Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
about
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and managementManagement of the older person with atrial fibrillation.Atrial Fibrillation: The New Epidemic of the Ageing WorldThe case for inpatient initiation of antiarrhythmic therapy.Antiarrhythmic drugs for atrial fibrillation.Pharmacological management of atrial fibrillation: one, none, one hundred thousand.Treating critical supraventricular and ventricular arrhythmias.Therapy of atrial fibrillation: rhythm control versus rate control.Pure class III antiarrhythmic drugs: focus on dofetilide.Pharmacotherapy of atrial fibrillation.Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials.Special problems with antiarrhythmic drugs in the elderly: safety, tolerability, and efficacy.Antiarrhythmic drugs: new agents and evolving concepts.Emergency management of atrial fibrillationSuperiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.Review of the current management of atrial fibrillation.Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits.Long QT syndrome: reduced repolarization reserve and the genetic link.Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical frameworkEmergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter.Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview.Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.Conversion of Persistent Atrial Fibrillation After Radiofrequency Ablation by Ibutilide.Predictors of long-term maintenance of normal sinus rhythm after successful electrical cardioversion.Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.Keep the QT interval: it is a reliable predictor of ventricular arrhythmias.Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm.Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should they Be?Ibutilide for the Cardioversion of Paroxysmal Atrial Fibrillation during Radiofrequency Ablation of Supraventricular Tachycardias.Safety and effectiveness of ibutilide in a community hospital.Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies.Ibutilide-induced alterations in electrocardiographic and spatial vectorcardiographic descriptors of ventricular repolarization.
P2860
Q26747032-8AA1747D-3366-42FF-A16A-927C18510181Q33144789-DDEE8E9A-2351-4FBD-8B3A-C905A76C9D68Q33168630-D84DBB12-916B-40BF-BC09-3B6E53BF5755Q33598024-CFE3F4AB-1F7D-47AF-9705-364506991624Q33821199-4A2D8655-72E2-4E7D-A585-2EFEC826D6D3Q33902193-418D1724-5024-498E-B9F9-740593A2EF65Q33909242-E93752E0-87AF-422E-A991-B7D53B12E20FQ33931009-212C7A8C-2C3B-4D57-8E03-C4EE0C5CB75AQ34126027-7B1D4E9B-9584-443D-8182-9DD063E9DE37Q34182375-8E09B510-250E-452A-A35C-54FE0E4AD4E2Q34422636-16AC8A13-A9B6-494D-A405-AB6995ADA714Q34491925-838E193F-E544-47D0-B085-3D5A545C8C4AQ34496116-3E4F36E1-FE69-4CDF-807E-B2F2D9F55395Q34989738-5E500647-CF26-4117-891E-E6323386DB54Q35073365-07078C67-F3CC-45C9-A4BA-0EB39ADDBA64Q35168643-B8AC8962-4A80-4E67-8585-CD68B7DAC497Q35368049-F3F6E065-CD13-495C-AD02-7FA5583A5ADAQ35574957-2B0FD4E1-90AB-4071-9CC2-8E874DF49E2FQ35582341-72E9C4A8-E83B-49C3-BA8C-479650C204F6Q35771784-39893337-BD99-4CD7-B2F1-369238E31566Q35814463-571363E3-AA15-46B3-A807-77A4C1C19139Q35892164-97BDEC24-AD8E-48B9-B1FD-E43E4DE3197EQ36216795-F2585BB0-AB11-4D1E-8671-F12F86853D20Q36335258-2A9633A3-B40D-4D9A-AA33-FCBA645665BDQ37013160-3E3A4A56-C4ED-41C6-814E-11BFF7B87BDDQ37018366-7C18EFE6-22D5-48A2-938F-4158B9FFE0A4Q37098991-DE60AB74-6A41-4422-9525-DAED20EDFCD8Q37378050-EE35A0EA-3994-409B-9A3A-B70B24A908BDQ37495653-CA7F05EA-0A9C-4FA7-9BF3-AFBE60FD8B4FQ38202066-7860AD88-29C6-4198-9675-6288743446B8Q38853630-98B45E95-46B7-4547-A9F2-96611A90B93BQ39018169-B13327DC-93EB-4826-B07C-CC411E85CC93Q40878614-A7BE6421-6EA7-4B45-AD31-32BE8B1236C3Q41720833-728AAC60-D7DA-4B34-8B5F-242BDD7C7A33Q41720852-C1E2862F-2F41-4686-AAB3-5042829C5DDDQ42126821-3F68B81C-A847-4A0C-8368-044768D08E22Q43580197-4BD48F14-22AF-4D11-B545-1850A15E3D84Q44360562-6E1B7E9C-0E32-41B7-9DD6-3B8417597476Q44844508-D602BCD5-BC7E-4F19-8B63-36857E81B4E0Q44966752-B778F5FA-F9E3-4C81-B1F4-B95EB4A921D7
P2860
Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@ast
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@en
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@nl
type
label
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@ast
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@en
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@nl
prefLabel
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@ast
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@en
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@nl
P2093
P1476
Efficacy of intravenous ibutil ...... lutter: a dose-response study.
@en
P2093
Ellenbogen KA
Meissner MC
Stambler BS
Vanderlugt JT
Wakefield LK
Wesley RC Jr
P304
P356
10.1016/0735-1097(96)00121-0
P407
P577
1996-07-01T00:00:00Z